No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Lineage Cell Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Lifesciences Conference
Assessing Lineage: Insights From 9 Financial Analysts
Scotiabank Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $73
Scotiabank Maintains Sector Outperform on Lineage, Lowers Price Target to $73
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target